Is progression-free survival a more relevant endpoint than overall survival in first-line HR+/HER2− metastatic breast cancer?

BACKGROUND: Hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−), metastatic breast cancer (MBC) accounts for 73% of all MBCs. Endocrine therapy (ET) is the basis of first-line (1L) therapy for patients with HR+/HER2− MBC. Novel therapies have demonstrated impro...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Cancer Manag Res
Auteurs principaux: Forsythe, Anna, Chandiwana, David, Barth, Janina, Thabane, Marroon, Baeck, Johan, Shor, Anastasiya, Tremblay, Gabriel
Format: Artigo
Langue:Inglês
Publié: Dove Medical Press 2018
Sujets:
Original Research
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5942396/
https://ncbi.nlm.nih.gov/pubmed/29765249
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CMAR.S162714
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires